Growth Metrics

Halozyme Therapeutics (HALO) Receivables - Net (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Receivables - Net for 16 consecutive years, with $441.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 43.06% to $441.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $441.3 million, a 43.06% increase, with the full-year FY2025 number at $441.3 million, up 43.06% from a year prior.
  • Receivables - Net was $441.3 million for Q4 2025 at Halozyme Therapeutics, up from $346.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $441.3 million in Q4 2025 to a low of $88.4 million in Q1 2021.
  • A 5-year average of $224.9 million and a median of $224.2 million in 2022 define the central range for Receivables - Net.
  • Peak YoY movement for Receivables - Net: skyrocketed 309.6% in 2021, then fell 12.86% in 2024.
  • Halozyme Therapeutics' Receivables - Net stood at $91.0 million in 2021, then surged by 154.0% to $231.1 million in 2022, then grew by 0.94% to $233.3 million in 2023, then surged by 32.24% to $308.5 million in 2024, then surged by 43.06% to $441.3 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Receivables - Net are $441.3 million (Q4 2025), $346.0 million (Q3 2025), and $315.1 million (Q2 2025).